Literature DB >> 15122741

Generalized log-rank test for mixed interval-censored failure time data.

Qiang Zhao1, Jianguo Sun.   

Abstract

This paper considers the problem of non-parametric treatment comparisons when mixed interval-censored failure time data are available, which often occurs in clinical trials and epidemiological studies. By mixed interval-censored data, we mean that the survival time of interest is observed to belong to an interval or to be right-censored. For the problem, we generalize the most commonly used log-rank test for right-censored survival data. Numerical studies are conducted and reported to evaluate and compare the proposed test with the existing method, which indicate that the presented method works well. We apply the method to a data set arising from an AIDS cohort study, that motivated the study. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15122741     DOI: 10.1002/sim.1746

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  A new class of generalized log rank tests for interval-censored failure time data.

Authors:  Xingqiu Zhao; Ran Duan; Qiang Zhao; Jianguo Sun
Journal:  Comput Stat Data Anal       Date:  2013-04       Impact factor: 1.681

2.  Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Authors:  Yingwei Qi; Katie L Allen Ziegler; Shauna L Hillman; Mary W Redman; Steven E Schild; David R Gandara; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

3.  Maximum likelihood estimation for the proportional odds model with mixed interval-censored failure time data.

Authors:  Liang Zhu; Xingwei Tong; Dingjiao Cai; Yimei Li; Ryan Sun; Deo K Srivastava; Melissa M Hudson
Journal:  J Appl Stat       Date:  2020-07-13       Impact factor: 1.404

Review 4.  Interval censoring.

Authors:  Zhigang Zhang; Jianguo Sun
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

5.  Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.

Authors:  Yunda Huang; Peter B Gilbert; David C Montefiori; Steve G Self
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

6.  Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

Authors:  Sergio Giralt; Luciano J Costa; David Maloney; Amrita Krishnan; Mingwei Fei; Joseph H Antin; Claudio Brunstein; Nancy Geller; Stacey Goodman; Parameswaran Hari; Brent Logan; Robert Lowsky; Muzaffar H Qazilbash; Firoozeh Sahebi; George Somlo; Scott Rowley; Dan T Vogl; David H Vesole; Marcelo Pasquini; Edward Stadtmauer
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-19       Impact factor: 5.742

7.  The Prognostic Value of Histopathologic Lesions in Native Kidney Biopsy Specimens: Results from the Boston Kidney Biopsy Cohort Study.

Authors:  Anand Srivastava; Ragnar Palsson; Arnaud D Kaze; Margaret E Chen; Polly Palacios; Venkata Sabbisetti; Rebecca A Betensky; Theodore I Steinman; Ravi I Thadhani; Gearoid M McMahon; Isaac E Stillman; Helmut G Rennke; Sushrut S Waikar
Journal:  J Am Soc Nephrol       Date:  2018-06-04       Impact factor: 10.121

8.  The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.

Authors:  Anand Srivastava; Insa M Schmidt; Ragnar Palsson; Astrid Weins; Joseph V Bonventre; Venkata Sabbisetti; Isaac E Stillman; Helmut G Rennke; Sushrut S Waikar
Journal:  Kidney Int Rep       Date:  2021-01-06

9.  Comparing survival functions with interval-censored data in the presence of an intermediate clinical event.

Authors:  Sohee Kim; Jinheum Kim; Chung Mo Nam
Journal:  BMC Med Res Methodol       Date:  2018-10-01       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.